Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00043927 · ClinicalTrials.gov registry record · Phase 3
Extensive Small Cell Lung Cancer Treatment Using An Investigational Drug Plus Chemotherapy In Chemotherapy-Naive Adults
A Phase 3 study, sponsored by GlaxoSmithKline.
- Completed
- Registry status
- Phase 3
- Development phase
- 760
- Enrollment target
NCT00043927 is a Phase 3 study that has completed, run by GlaxoSmithKline. The registered enrollment target is 760 participants.
The verdict
NCT00043927, a Phase 3 study, has completed, sponsored by GlaxoSmithKline.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 760 participants
- Enrollment target
Study Summary
This study will gather and compare data about the effectiveness and safety of two different treatments for extensive Small Cell Lung Cancer (SCLC) in patients who have not received previous chemotherapy. One treatment will use an investigational drug in combination with an FDA approved chemotherapy. The other treatment will use a combination of two FDA approved chemotherapy drugs.
Interventions
- DRUG etoposide/cisplatin
- DRUG topotecan/cisplatin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 760 participants |
| Start Date | 2001-04 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00043927
The ClinicalTrials.gov registry entry for NCT00043927 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 760 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is GlaxoSmithKline, which has 1,345 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which etoposide/cisplatin is the first listed.
NCT00043927 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00043927 about?
NCT00043927 is a clinical study titled "Extensive Small Cell Lung Cancer Treatment Using An Investigational Drug Plus Chemotherapy In Chemotherapy-Naive Adults". This study will gather and compare data about the effectiveness and safety of two different treatments for extensive Small Cell Lung Cancer (SCLC) in patients who have not received previous chemotherapy. One treatment will use an investigational drug in combination with an FDA approved chemotherapy....
What is the current status of trial NCT00043927?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 760 participants. The study started on 2001-04.
What interventions are being tested in trial NCT00043927?
The interventions under investigation include: etoposide/cisplatin (DRUG), topotecan/cisplatin (DRUG).
Who is sponsoring clinical trial NCT00043927?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.